Compositions that inhibit proliferation of cancer cells
AssigneeUniversity of Rochester
InventorsHartmut Land, Laurent Deleu
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods for reducing the proliferation of cancer cells through targeted interactions with integrins.
Claims131
A method of reducing the proliferation of a cancer cell which comprises inhibiting ligand binding to an integrin receptor on the cancer cell, wherein the integrin receptor comprises an integrin.
A method of reducing the proliferation of a cancer cell which comprises reducing integrin-integrin interaction, integrin receptor clustering interaction, or integrin-non-integrin protein interaction.
A method of reducing the proliferation of a cancer cell which comprises reducing the production of an integrin by the cancer cell.
A method of reducing the proliferation of a cancer cell which comprises reducing the production of an integrin receptor ligand by the cancer cell.
A method of reducing the proliferation of a cancer cell which comprises interfering with an integrin signaling pathway.
A method of isolating molecules that bind with a target molecule selected from the group consisting, B4 integrin, alpha6 integrin, and the gamma2 subunit of laminin5 comprising 1) contacting a library of molecules with the target molecule and 2) collecting molecules that bind the target molecule producing an enriched population of molecules.
A method of assessing a subject's risk of developing cancer comprising determining the amount of A6 present in a target cell obtained from the subject, wherein a determination of increased levels of A6 correlates with an increased risk of cancer.
A method of assessing a subject's risk of acquiring cancer comprising determining the amount of B4 present in a target cell obtained from the subject, wherein a determination of increased levels of B4 correlates with an increased risk of cancer.
A method of assessing a subject's risk of acquiring cancer comprising determining the amount of laminin5 present in a target cell obtained from the subject, wherein a determination of increased levels of laminin5 correlates with an increased risk of cancer.
A method of assessing a subject's risk of acquiring cancer comprising determining the amount of ganima2 subunit present in a target cell obtained from the subject, wherein a determination of increased levels of gamma2 subunit correlates with an increased risk of cancer.
A method of reducing the proliferation of a cancer cell in a patient which comprises administering to the patient a composition which inhibits ligand binding to an integrin receptor on the cancer cell, wherein the integrin receptor comprises an integrin.
A method of reducing the proliferation of a cancer cell in a patient which comprises administering to the patient a composition which reduces integrin-integrin interaction, integrin receptor clustering interaction, or integrin-non-integrin protein interaction.
A method of reducing the proliferation of a cancer cell in a patient which comprises administering to the patient a composition which reduces the production of an integrin or laminin by the cancer cell.
A method of reducing the proliferation of a cancer cell in a patient which comprises administering to the patient a composition which interfers with an integrin signaling pathway.
A method of reducing the proliferation of a cancer cell in a patient which comprises administering to a patient a vector comprising coding sequence for a protein or peptide which inhibits ligand binding to integrin receptors on cancer cells wherein the coding sequence is under the control of a promoter which functions in mammalian cells.
A method of reducing the proliferation of a cancer cell in a patient which comprises administering to a patient a vector comprising coding sequence for a protein or peptide which prevents integrin receptor subunits from interacting with one another, prevents integrin receptor clustering interaction, or prevents integrin receptor subunits from interacting with other proteins on cancer cells wherein the coding sequence is under the control of a promoter which functions in mammalian cells.
A method of reducing the proliferation of a cancer cell in a patient which comprises administering to a patient a vector comprising coding sequence for a protein or peptide which prevents intcgrin receptor subunits from interacting with one another, prevents integrin receptor clustering interaction, or prevents integrin receptor subunits from interacting with other proteins in cancer cells wherein the coding sequence is under the control of a promoter which functions in mammalian cells.
A method of reducing the proliferation of a cancer cell in a patient which comprises administering to a patient a vector comprising coding sequence for a protein or peptide which interferes with integrin subunit or laminin production wherein the coding sequence is under the control of a promoter which functions in mammalian cells.
A method of reducing the proliferation of a cancer cell in a patient which comprises administering to a patient a vector comprising coding sequence for a protein or peptide which interferes with an integrin signaling pathway of cells wherein the coding sequence is under the control of a promoter which functions in mammalian cells.
A cell assay system comprising at least two manipulated genes, wherein the expression of the genes is controlled in the cell assay system, and wherein the genes are involved in a disease state.
Dependencies are inferred from the claim text.